At the news
? NEUTRALIMPACT 4/10 PRESS-RELEASE filed Nov 19, 2026 at 09:09 ET
Lisata Therapeutics announced a 1-for-15 reverse stock split, effective November 23, 2026, to regain compliance with Nasdaq's minimum bid price requirement. The split reduces outstanding shares from ~10.8M to ~0.7M and follows a recent S-3 shelf registration that registered ~350M shares for resale by selling stockholders, creating potential overhang.
- Reverse stock split ratio of 1-for-15, effective November 23, 2026
- Outstanding shares reduced from ~10.8M to ~0.7M
- Stockholders approved the split at the November 9, 2026 annual meeting
- No fractional shares will be issued; cash paid in lieu
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access